aTyr Pharma, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [], 20__ Debt SecuritiesIndenture • November 9th, 2023 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York
Whereas, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
aTyr Pharma, Inc. and _____________, As Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of __________Preferred Stock Warrant Agreement • November 9th, 2023 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York
This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
aTyr Pharma, Inc. and _____________, As Warrant Agent Form of Common Stock Warrant Agreement Dated as of __________Common Stock Warrant Agreement • November 9th, 2023 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York
This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
aTyr Pharma, Inc. and _____________, As Warrant Agent Form of Debt Securities Warrant Agreement Dated as of __________Debt Securities Warrant Agreement • November 9th, 2023 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York
This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between aTyr Pharma, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
